Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Martin LeWinter MD, FACC, FAHA

Martin M LeWinter MD, FACC, FAHA

Professor of Medicine and Molecular Physiology and Biophysics; Director, Heart Failure and Cardiomyopathy Program, University of Vermont College of Medicine, Colchester, Vermont

Dr. LeWinter is Professor of Medicine and Molecular Physiology and Biophysics and Director of the Heart Failure and Cardiomyopathy Program at the University of Vermont. He received his undergraduate degree from Columbia University, his M.D. from New York University and sub-specialty training in Cardiovascular Disease at University of California, San Diego.  In addition to heart failure, cardiac hypertrophy and myocardial dysfunction Dr. LeWinter has had a longstanding interest in pericardial disease. Dr. LeWinter has received continuous research support from the NIH for over 35 years and is the author of over 190 original research papers, over 60 book chapters and review articles, and the Editor of two books. He is a Fellow of the American Heart Association, the American College of Cardiology, the Cardiovascular Section of the American Physiological Society and the International Academy of Cardiovascular Sciences, and a member of the Association of University Cardiologists. Dr. LeWinter has served on numerous Editorial Boards and research review committees and is an Associate Editor of the journals Circulation and Coronary Artery Disease. He is a former member of the Cardiovascular Subspecialty Board and currently serves on the Self-Evaluation Process Committee of The American Board of Internal Medicine.

Disclosures

1. Provide(d) Research Support for: Novartis and Medtronic

2. Serve(d) as Consultant with: Cytokinetics and Merck

 

Recent Contributions to PracticeUpdate:

  1. Interleukin-1 Trap Rilonacept Beneficial in Recurrent Pericarditis
  2. Pericardial Diseases in Patients With Cancer
  3. Pre- and Post-Pericardiocentesis Echo-Doppler Features of Effusive–Constrictive Pericarditis
  4. Maintained Anakinra Treatment Prevents Recurrent Pericarditis in Patients With Colchicine Resistance and Corticosteroid Dependence
  5. Differential Response to Dopamine or Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction
  6. 2015 ESC Guidelines for Pericardial Diseases
  7. Treatment With Colchicine in Acute Myocardial Infarction
  8. Factors Influencing Acute Pericarditis Outcomes
  9. MY APPROACH to Patients With Acute Pericarditis
  10. Colchicine Reduces Multiple Recurrences of Pericarditis

Most Read This Week

Recently Updated